A method for the 11C-labelling of proteins for use in positron emission tomography is presented. Human iron-free transferrin and human serum albumin were treated with [11C]cyanogen bromide of high specific radioactivity under physiological conditions to give the labelled proteins in high radiochemical yields using a simple and rapid procedure. In a typical experiment, 2.0 GBq of [11C]albumin was obtained in 28-32 min synthesis time counted from the end of bombardment. The radiochemical purity was in all cases > 98% and the specific radioactivity varied with the amount of protein between 10.7-141 GBq mumol-1 (0.3-3.8 Ci mumol-1). The radiochemical yield of labelled product as a function of pH and protein concentration was studied. The labelled products were characterized using both high performance liquid chromatography and high performance capillary electrophoresis with u.v.-and radiodetection in series.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0969-8043(94)90128-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Doxorubicin-loaded PEGylated liposome modified with ANGPT2-specific peptide for integrative glioma-targeted imaging and therapy.
Mater Today Bio
February 2025
Department of Nuclear Medicine, Gansu Provincial Cancer Hospital, Lanzhou, Gansu, 730050, China.
Liposomal nanocarriers are able to carry peptides for efficient and selective delivery of radioactive tracer and drugs into the tumors. Angiopoietin 2 (ANGPT2) is an excellent biomarker for precise diagnosis and therapy of glioma. The present study aimed to design ANGPT2-specific peptides to modify the surface of nanoliposomes containing doxorubicin (Dox) for integrative imaging and targeting therapy of glioma.
View Article and Find Full Text PDFAxillary Lymph Node Metastasis in Papillary Thyroid Carcinoma at Early Perioperative Period: Report of a Case and Review of the Literature.
Acta Med Indones
October 2024
Akdeniz University, Faculty of Medicine, Department of General Surgery, 07070, Antalya, Turkey.
A 36-year-old woman with a history of neck swelling was diagnosed with papillary thyroid carcinoma, a common but typically slow-growing thyroid cancer with a good prognosis. Despite frequent lymph node metastasis, mortality rates are low. This cancer can rarely spread to unusual areas like the axillary region.
View Article and Find Full Text PDFPET Quantification in Healthy Humans of Cyclooxygenase-2, a Potential Biomarker of Neuroinflammation.
J Nucl Med
January 2025
Intramural Research Program, National Institute of Mental Health, Bethesda, Maryland;
Cyclooxygenase-2 (COX-2) is present in a healthy brain at low densities but can be markedly upregulated by excitatory input and by inflammogens. This study evaluated the sensitivity of the PET radioligand [C]-6-methoxy-2-(4-(methylsulfonyl)phenyl)--(thiophen-2-ylmethyl)pyrimidin-4-amine ([C]MC1) to detect COX-2 density in a healthy human brain. The specificity of [C]MC1 was confirmed using lipopolysaccharide-injected rats and transgenic mice expressing the human gene, with 120-min baseline and blocked scans using COX-1 and COX-2 selective agents.
View Article and Find Full Text PDFFrom collective to individual radon risk exposure: An insight into the current European regulation.
Environ Int
January 2025
Dipartimento di Geoscienze, Università di Padova, Padova, Italy.
Radon (Rn) is a radioactive gas with well-documented harmful effects; the World Health Organization has confirmed it as a cancerogenic for humans. These detrimental effects have prompted Europe to establish national reference levels to protect the exposed population. This is reflected in European directive 59/2013/EURATOM, which has been transposed into the national regulations of EU Member States.
View Article and Find Full Text PDFLutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy.
EJNMMI Radiopharm Chem
January 2025
Department of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac, 52750, Mexico.
Background: Cancer immunotherapy is a relatively new approach to cancer treatment. Peptides that target specific pathways and cells involved in immunomodulation can potentially improve the efficacy of cancer therapy. Recently, we reported iPD-L1 as a novel inhibitor peptide that specifically targets the cancer cell ligand PD-L1 (programmed death ligand 1).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!